{"id":3433,"date":"2025-04-29T23:02:20","date_gmt":"2025-04-29T23:02:20","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/04\/29\/bridgebio-attruby-attr-cm-heart-drug-sales\/"},"modified":"2025-04-29T23:02:20","modified_gmt":"2025-04-29T23:02:20","slug":"bridgebio-attruby-attr-cm-heart-drug-sales","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/04\/29\/bridgebio-attruby-attr-cm-heart-drug-sales\/","title":{"rendered":"STAT+: Sales of BridgeBio\u2019s new heart drug blow past expectations"},"content":{"rendered":"<p>    STAT+: Sales of BridgeBio\u2019s new heart drug blow past expectations<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>BridgeBio\u2019s recently approved heart drug brought in $36.7 million in sales in the first quarter, blowing past expectations as the biotech continues to see a strong demand for its first major commercial product.\u00a0<\/p>\n<p>Analysts had estimated that the treatment, called Attruby, would bring in sales of $12 million, but Wall Street\u2019s \u201cwhisper number\u201d was $17 million to $20 million.<\/p>\n<p>Between the <a href=\"https:\/\/www.statnews.com\/2024\/11\/22\/bridgebio-attruby-acoramidis-attr-cm-fda-approval\/\">approval<\/a> of the treatment last November and the end of the last week, over 750 health care providers have written more than 2,000 patient prescriptions, BridgeBio said while reporting earnings Tuesday. Analysts estimated about 1,700 prescriptions through the first quarter.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/04\/29\/bridgebio-attruby-attr-cm-heart-drug-sales\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Elaine Chen<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/04\/29\/bridgebio-attruby-attr-cm-heart-drug-sales\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Sales of BridgeBio\u2019s new heart drug blow past expectations BridgeBio\u2019s recently approved heart drug brought in $36.7 million in sales in the first quarter, blowing past expectations as the biotech continues to see a strong demand for its first major commercial product.\u00a0 Analysts had estimated that the treatment, called Attruby, would bring in sales [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2486,2152],"tags":[2150],"class_list":["post-3433","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-cardiovascular-disease","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/3433"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=3433"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/3433\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=3433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=3433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=3433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}